This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Amgen's (AMGN) KRAS Inhibitor Gets Nod for Lung Cancer in EU
by Zacks Equity Research
Amgen's (AMGN) Lumykras is the first targeted therapy approved for patients with KRAS G12C mutation in Europe.
Absci (ABSI) Inks Research Agreement With Merck, Stock Up
by Zacks Equity Research
Absci (ABSI) signs a deal with Merck for using its AI-powered drug creation platform to produce enzymes for Merck's biomanufacturing applications with an option for the development of three novel drugs.
Should You Invest in the VanEck Biotech ETF (BBH)?
by Zacks Equity Research
Sector ETF report for BBH
Amgen (AMGN) Inks Multi-Target Deal to Make Protein Therapeutics
by Zacks Equity Research
Amgen (AMGN) signs a collaboration agreement with Generate Biomedicines to develop protein therapeutics across several therapeutic areas and multiple modalities.
Top Research Reports for Alphabet, salesforce & Starbucks
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), salesforce.com, inc. (CRM), and Starbucks Corporation (SBUX).
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for IBB
Amgen (AMGN) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Amgen (AMGN) closed at $227.84, marking a +0.51% move from the previous day.
Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed at $226.69 in the latest trading session, marking a +0.76% move from the prior day.
Should You Invest in the iShares Biotechnology ETF (IBB)?
by Zacks Equity Research
Sector ETF report for IBB
Amgen (AMGN) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed at $225.77 in the latest trading session, marking a +0.27% move from the prior day.
Ligand (LGND) Stock Surges 60% YTD: What's Driving the Rally?
by Zacks Equity Research
Strong demand for two of Ligand's (LGND) partnered drugs, AMGN's Krprolis and GILD's Veklury, is driving its royalties. This is likely to continue next year.
Biotech Stock Roundup: Regulatory Updates From BIIB, AMGN and NVAX & More
by Zacks Equity Research
Regulatory and other pipeline updates from Biogen (BIIB) and Novavax (NVAX) have been the biotech sector's few key highlights during the past week.
Amgen (AMGN) Stock Moves -1.13%: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed the most recent trading day at $219.99, moving -1.13% from the previous trading session.
Amgen, AstraZeneca's Asthma Drug Tezepelumab Gets FDA Nod
by Zacks Equity Research
Amgen (AMGN) and AstraZeneca's (AZN) Tezspire is the only biologic medicine approved by the FDA to treat severe asthma with no phenotype limitation and irrespective of biomarker levels.
Amgen (AMGN) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed at $213.74 in the latest trading session, marking a +1.11% move from the prior day.
Sanofi (SNY) Multiple Myeloma Phase III Study Meets Goal
by Zacks Equity Research
Sanofi's (SNY) phase III study on Sarclisa is the first to meet the primary endpoint of MRD negativity in transplant-eligible patients with newly diagnosed multiple myeloma.
Top Stock Reports for Visa, UPS & TotalEnergies
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), United Parcel Service, Inc. (UPS), and TotalEnergies SE (TTE).
Radius (RDUS) Announces Data on Breast Cancer Drug, Abalo-TDS
by Zacks Equity Research
Radius Health (RDUS) provides detailed results on breast cancer drug and from the phase III wearABLe study.
Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed at $213.53 in the latest trading session, marking a +1.05% move from the prior day.
The Zacks Analyst Blog Highlights: Vertex Pharma, Amgen, Blueprint Medicines, Deciphera Pharma and CTI BioPharma
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Vertex Pharma, Amgen, Blueprint Medicines, Deciphera Pharma and CTI BioPharma
Amgen (AMGN) Down 7.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Amgen (AMGN) Kyprolis Gets FDA Nod for Use With Darzalex Faspro
by Zacks Equity Research
Amgen (AMGN) gets FDA nod for the label expansion of Kyprolis in combination with Darzalex Faspro and dexamethasone for treating patients with multiple myeloma at first or subsequent relapse.
Biotech Stock Roundup: VRTX, AMGN's Pipeline Updates, BPMC's Acquisition & More
by Zacks Equity Research
Pipeline updates from Vertex (VRTX) and Amgen (AMGN) and other acquisition and regulatory updates have been the biotech sector's few key highlights during the past week.
Bristol Myers' (BMY) Plaque Psoriasis Drug Filings Get Through
by Zacks Equity Research
Bristol Myers' (BMY) applications seeking approval for deucravacitinib are accepted by the regulatory bodies of both the United States and the European Union.
Ligand's (LGND) Drug-Developing Technologies Holds Potential
by Zacks Equity Research
Ligand's (LGND) Captisol technology is a key driver for its topline. The company plans to spin off another potential technology platform, OmniAb, into a separate company.